leisure time -WSS

leisure time

author：explore 2025-09-30 16:25:56 - browse：33

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

focus

WSS

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO: Palliative care found as helpful given virtually as in person

Ionis drug prevents swelling attacks due to hereditary angioedema

Verily hires former Apple Health leader as chief scientific officer

Dramatically reducing cancer deaths requires the PASTEUR Act

Ultragenyx gene therapy for rare liver ailment succeeds in late

knowledge

leisure time

hotspot

In Memoriam: Notable people who died in 2023

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Malaria cases in Florida and Texas: Here’s what you need to know

Let's speed up science by embracing open access publishing

As demand for Covid shots wanes, Moderna seeks its next success

BMI, flaws aside, is found to be useful estimate of body fat in youth

Guidelines to prevent youth baseball injuries need more muscle

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Duchenne breakthrough therapy leaves behind pioneering families

Biden calls for immediate release of Niger's president amid apparent coup

hotspot

NIH documents show early flaws of $1.6 billion long Covid program

Ionis drug prevents swelling attacks due to hereditary angioedema

Stem cell clinics for heart failure: buyer be wary

My superpower is killing ticks

Intellia reports positive results for its CRISPR

Cord blood banking comes at a high cost to babies

focus

entertainment

focus

entertainment